Ekso Bionics (NASDAQ:EKSO) Stock Price Crosses Above Fifty Day Moving Average – What’s Next?

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) shares passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $8.93 and traded as high as $10.28. Ekso Bionics shares last traded at $10.23, with a volume of 45,151 shares.

Analysts Set New Price Targets

EKSO has been the topic of several recent research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Ekso Bionics in a research report on Monday, December 22nd. HC Wainwright downgraded shares of Ekso Bionics from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 31st. Finally, Wall Street Zen upgraded shares of Ekso Bionics to a “hold” rating in a report on Saturday, December 13th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average price target of $6.00.

Ekso Bionics Trading Up 6.6%

The company has a quick ratio of 1.07, a current ratio of 1.63 and a debt-to-equity ratio of 0.09. The firm’s fifty day moving average is $9.13 and its two-hundred day moving average is $6.16. The firm has a market cap of $37.95 million, a P/E ratio of -2.07 and a beta of 0.79.

Insider Buying and Selling

In other news, major shareholder Daniel Asher acquired 15,540 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were acquired at an average cost of $12.30 per share, with a total value of $191,142.00. Following the transaction, the insider owned 270,432 shares in the company, valued at $3,326,313.60. The trade was a 6.10% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 6.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Ekso Bionics

A number of hedge funds and other institutional investors have recently bought and sold shares of EKSO. Virtu Financial LLC bought a new position in shares of Ekso Bionics during the third quarter valued at approximately $57,000. Shay Capital LLC purchased a new stake in shares of Ekso Bionics in the 3rd quarter worth approximately $67,000. Citadel Advisors LLC purchased a new stake in shares of Ekso Bionics in the 3rd quarter worth approximately $198,000. Geode Capital Management LLC increased its position in Ekso Bionics by 68.9% during the 4th quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock valued at $218,000 after buying an additional 10,281 shares in the last quarter. Finally, Consolidated Portfolio Review Corp purchased a new position in Ekso Bionics during the third quarter valued at $333,000. Hedge funds and other institutional investors own 6.42% of the company’s stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.